Pharmaceutical

EC approves BMS’ Camzyos for hypertrophic cardiomyopathy

The European Commission has approved Bristol Myers Squibb’s Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy.

Jun 27, 2023 - 20:00
EC approves BMS’ Camzyos for hypertrophic cardiomyopathy
The European Commission has approved Bristol Myers Squibb’s Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy.
Read the original article

Tags:

Previous Article

Tonix to acquire Upsher-Smith’s migraine products

Next Article

Vertex and Lonza to establish T1D cell therapy manufacturing facility

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Cell and gene therapies could be a safer bet than other drugs

Cell and gene therapies could be a safer bet than other...

Oct 12, 2023

STAT+: Pharmalittle: Lilly’s Mounjaro helped people lose 15.7% of body weight; Sanofi earnings boosted by Dupixent

STAT+: Pharmalittle: Lilly’s Mounjaro helped people los...

Apr 27, 2023

Opinion: The new fertility technology IVG is supposed to change everything. Don’t count on it yet

Opinion: The new fertility technology IVG is supposed t...

Oct 2, 2023